Angia Rx Life Science Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-01-2025
- Paid Up Capital ₹ 0.50 M
as on 04-01-2025
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
About Angia Rx Life Science
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Angia Rx Life Science Private Limited India is Mohit Singhal as CEO. Mohit Singhal, Shilpi Bansal, and Ajay Kumar serve as directors at the Company.
- CIN/LLPIN
U24234UR2019PTC009892
- Company No.
009892
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jun 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Haridwar, Uttarakhand, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Angia Rx Life Science Private Limited offer?
Angia Rx Life Science Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup, Malaria Medicine, Antibiotic Tablets, Capsule & Syrup, Osteoporosis Medications, Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine, Cardiovascular Drugs & Medication.
Who are the key members and board of directors at Angia Rx Life Science?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mohit Singhal | CEO | 23-Sep-2023 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohit Singhal  | Director | 11-Jun-2019 | Current |
| Shilpi Bansal | Director | 11-Jun-2019 | Current |
| Ajay Kumar | Director | 20-Aug-2023 | Current |
Financial Performance of Angia Rx Life Science.
Angia Rx Life Science Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Angia Rx Life Science?
In 2020, Angia Rx Life Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Angia Rx Life Science?
Angia Rx Life Science has a workforce of 6 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Angia Rx Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Angia Rx Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
